What is the Market's View on AnaptysBio Inc (ANAB) Stock's Price and Volume Trends Thursday?

AnaptysBio Inc (ANAB) stock has risen 4.15% over the past week and gets a Bullish rating from InvestorsObserver Sentiment Indicator.

AnaptysBio Inc has a Bullish sentiment reading. Find out what this means for you and get the rest of the rankings on ANAB!

See Full ANAB Report

What is Stock Sentiment?

In investing, sentiment generally means whether or not a given security is in favor with investors. It is typically a pretty short-term metric that relies entirely on technical analysis. That means it doesn’t incorporate anything to do with the health or profitability of the underlying company. Price action is generally the best indicator of sentiment. For a stock to go up, investors must feel good about it. Similarly, a stock that is in a downtrend must be out of favor. InvestorsObserver’s Sentiment Indicator considers price action and recent trends in volume. Increasing volumes often mean that a trend is strengthening, while decreasing volumes can signal that a reversal could come soon. The options market is another place to get signals about sentiment. Since options allow investors to place bets on the price of a stock, we consider the ratio of calls and puts for stocks where options are available.

What's Happening With ANAB Stock Today?

AnaptysBio Inc (ANAB) stock is trading at $24.58 as of 12:00 PM on Thursday, Mar 21, a gain of $0.64, or 2.65% from the previous closing price of $23.94. The stock has traded between $24.27 and $24.73 so far today. Volume today is light. So far 82,120 shares have traded compared to average volume of 297,301 shares.

More About AnaptysBio Inc

AnaptysBio Inc is clinical-stage biotechnology company. It is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company develops product candidates to address emerging biological targets using its proprietary, antibody discovery technology platform, which is designed to replicate, in vitro, the natural process of antibody generation. Its product candidates are ANB020, ANB019, and Checkpoint receptor agonist. The entity generates revenue from the collaborative research and development arrangements. Click Here to get the full Stock Report for AnaptysBio Inc stock.